Background-Left ventricular ejection fraction (LVEF) and infarct size (ISZ) are key predictors of long-term survival after myocardial infarction (MI). However, little is known about the biochemical pathways driving LV dysfunction after MI. To identify novel biomarkers predicting post-MI LVEF and ISZ, we performed metabolic profiling in the GIPS-III randomized clinical trial (Glycometabolic Intervention as Adjunct to Primary Percutaneous Intervention in ST Elevation Myocardial Infarction). We also investigated the metabolic footprint of metformin, a drug associated with improved post-MI LV function in experimental studies. Methods and Results-Participants were patients with ST-segment-elevated MI who were randomly assigned to receive metform...
Background: Left ventricular hypertrophy (LVH) is highly prevalent in patients with coronary artery ...
Diastolic dysfunction is an important predictor of poor outcome after myocardial infarction. Metform...
Introduction Diastolic dysfunction is an important predictor of poor outcome after myocardial infarc...
Background-Left ventricular ejection fraction (LVEF) and infarct size (ISZ) are key predictors of lo...
Objective Metformin affects low density lipoprotein (LDL) and high density (HDL) subfractions in the...
IMPORTANCE Metformin treatment is associated with improved outcome after myocardial infarction in pa...
IMPORTANCE Metformin treatment is associated with improved outcome after myocardial infarction in pa...
Increased myocardial infarct (MI) size is associated with higher risk of developing left ventricular...
Despite clear advances in reperfusion therapy and pharmacological treatment, a large proportion of p...
ObjectiveMetformin affects low density lipoprotein (LDL) and high density (HDL) subfractions in the ...
Background: Left ventricular hypertrophy (LVH) is highly prevalent in patients with coronary artery ...
Diastolic dysfunction is an important predictor of poor outcome after myocardial infarction. Metform...
Introduction Diastolic dysfunction is an important predictor of poor outcome after myocardial infarc...
Background-Left ventricular ejection fraction (LVEF) and infarct size (ISZ) are key predictors of lo...
Objective Metformin affects low density lipoprotein (LDL) and high density (HDL) subfractions in the...
IMPORTANCE Metformin treatment is associated with improved outcome after myocardial infarction in pa...
IMPORTANCE Metformin treatment is associated with improved outcome after myocardial infarction in pa...
Increased myocardial infarct (MI) size is associated with higher risk of developing left ventricular...
Despite clear advances in reperfusion therapy and pharmacological treatment, a large proportion of p...
ObjectiveMetformin affects low density lipoprotein (LDL) and high density (HDL) subfractions in the ...
Background: Left ventricular hypertrophy (LVH) is highly prevalent in patients with coronary artery ...
Diastolic dysfunction is an important predictor of poor outcome after myocardial infarction. Metform...
Introduction Diastolic dysfunction is an important predictor of poor outcome after myocardial infarc...